Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Astrocytoma

    New York, NY

    Search
    Astrocytoma
    New York, NY
    Show Map
    Map View
    New York, NY
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      34 Astrocytoma Trials near New York, NY

      Power is an online platform that helps thousands of Astrocytoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Selumetinib vs. Chemotherapy for Brain Cancer

      New York, New York
      This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Concurrent Malignancy, Heart Disease, Others
      Must Not Be Taking:Investigational Agents, Vitamin E

      170 Participants Needed

      Adaptive Radiotherapy for Brain Tumor

      New York, New York
      The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Prior Malignancy, Others

      20 Participants Needed

      Dabrafenib + Trametinib for Brain Tumors

      New York, New York
      This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:1 - 99

      Key Eligibility Criteria

      Disqualifiers:Severe Toxicities, Others
      Must Be Taking:Dabrafenib, Trametinib

      163 Participants Needed

      Veliparib + Radiation + Temozolomide for Brain Cancer

      New York, New York
      This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:3 - 25

      Key Eligibility Criteria

      Disqualifiers:Diffuse Astrocytoma, Oligodendrogliomas, PXA, Others
      Must Not Be Taking:Anti-cancer Agents

      38 Participants Needed

      Bevacizumab for Brain Cancer

      New York, New York
      The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of either surgical resection, external beam radiation or both. All patients experience a recurrence after first-line therapy, so improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. It is unknown if currently used intravenous (IV) therapies even cross the blood brain barrier (BBB). The investigators have shown in a previous phase I trial that a single Super-selective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (up to 15mg/kg) is safe and effective in the treatment of recurrent GBM. Therefore, this phase I/II clinical research trial is an extension of that trial in that the investigators seek to test the hypothesis that repeated dosing of intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab should be combined with repeated selected intraarterial Bevacizumab to improve progression free and overall survival. The investigators expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for malignant glioma, and may alter the way these drugs are delivered to the patients in the near future.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Lactation, Significant Medical Conditions
      Must Not Be Taking:Bevacizumab

      54 Participants Needed

      Dabrafenib + Trametinib After Radiation for Brain Cancer

      New York, New York
      This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:3 - 25

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Cardiac Disease, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Antidepressants, Others

      58 Participants Needed

      Vorasidenib + Pembrolizumab for Brain Cancer

      New York, New York
      Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Recent Cancer Therapy, Multiple Radiation, Others
      Must Not Be Taking:IDH Inhibitors, PD1 Inhibitors

      72 Participants Needed

      Proton Beam vs IMRT for Brain Cancer

      New York, New York
      This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. It is not yet known if proton beam radiation therapy is more effective than photon-based beam intensity-modulated radiation therapy in treating patients with glioma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Prior Malignancy, Prior Cranial Radiotherapy, Prior Chemotherapy, Neurologic Or Psychiatric Disease, Others
      Must Not Be Taking:Memantine

      120 Participants Needed

      Cetuximab + Reirradiation for Brain Cancer

      New York, New York
      Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Leptomeningeal Disease, Allergic To CTX, Others

      37 Participants Needed

      Virus-Based Drug Therapy for Brain Tumor

      New York, New York
      This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Systemic Malignancy, Chronic Infections, Others
      Must Not Be Taking:Antivirals, Immunosuppressants, Anti-VEGF

      62 Participants Needed

      SurVaxM Vaccine for Brain Cancer

      New York, New York
      This trial tests the SurVaxM vaccine, which helps the immune system target and destroy cancer cells, in children and young adults with certain difficult-to-treat brain cancers. The vaccine works by teaching the immune system to recognize a protein found in cancer cells. Additional substances are used to make the immune response stronger.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Autoimmune Disease, Others
      Must Not Be Taking:Cannabidiol, Medical Marijuana, Others

      35 Participants Needed

      INCB7839 for Brain Cancer in Children

      New York, New York
      This trial tests INCB7839, a drug that blocks proteins helping cancer cells grow, on children with tough-to-treat brain tumors that have returned or grown after initial treatment. The drug works by stopping a protein needed for tumor growth from being released.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:3 - 21

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      13 Participants Needed

      Combination Therapy for Brain Cancer

      New York, New York
      This trial is testing a combination of three drugs to treat a specific type of brain tumor called diffuse midline gliomas (DMGs). These drugs aim to stop the tumor from growing by blocking enzymes that the cancer cells need. The trial focuses on patients with DMGs because current treatments are not very effective for them.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:2 - 39

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Others
      Must Not Be Taking:CYP3A4/5 Inhibitors, Inducers

      360 Participants Needed

      Radiation Therapy + Temozolomide for Brain Tumor

      New York, New York
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Uncontrolled Infection, HIV, Others

      540 Participants Needed

      Safusidenib for Brain Cancer

      New York, New York
      This trial is testing a new oral medication called safusidenib for patients with certain types of brain tumors that have not responded to other treatments. The drug works by targeting a specific gene mutation to slow down tumor growth. The study will evaluate the safety and effectiveness of different doses of the medication.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Infections, Gastrointestinal, Psychiatric, Others
      Must Not Be Taking:CYP2C8, CYP2C9, CYP3A4 Substrates

      125 Participants Needed

      177Lu-PSMA-617 for Brain Cancer

      New York, New York
      The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chronic Kidney Disease, Viral Hepatitis, Others
      Must Be Taking:Dexamethasone

      20 Participants Needed

      Vorinostat + Temozolomide for Brain Cancer

      New York, New York
      This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Cancers, Active Infection, HIV, Others
      Must Not Be Taking:Antiretrovirals, Valproic Acid

      83 Participants Needed

      Selumetinib for Pediatric Brain Cancer

      New York, New York
      This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:3 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Seizures, Significant Organ Dysfunction, Others
      Must Not Be Taking:Anticancer Agents, MEK Inhibitors

      220 Participants Needed

      Telaglenastat + Radiation Therapy + Temozolomide for Astrocytoma

      New York, New York
      This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Prior Chemotherapy, Prior Brain Radiation, Uncontrolled Illness, Active Malignancy, Others
      Must Not Be Taking:Investigational Agents

      40 Participants Needed

      AZD9574 for Advanced Solid Tumors

      New York, New York
      This trial tests AZD9574, a new drug that stops cancer cells from repairing themselves. It targets patients with advanced or relapsed cancers who need new treatment options. The drug is tested alone and in combination with other cancer-fighting drugs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Severe Pancytopenia, Uncontrolled Seizures, Severe Brain Injury, Others
      Must Be Taking:PARPi, TMZ

      695 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Astrocytoma Trial

      Radiation and Temozolomide vs. PCV Chemotherapy for Brain Tumor

      New York, New York
      Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Nursing, HIV, Active Infection, Others
      Must Not Be Taking:Retroviral Therapy

      305 Participants Needed

      G207 + Radiation for Pediatric Brain Tumor

      New York, New York
      This trial tests a new treatment for children with aggressive brain tumors that haven't responded to other treatments. The treatment uses a special virus injected into the tumor, followed by a small dose of radiation. The virus kills cancer cells and helps the immune system fight the tumor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:3 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Secondary Glioma, Others
      Must Not Be Taking:Anticancer Drugs, HSV Drugs

      35 Participants Needed

      Selumetinib + Vinblastine for Low-Grade Glioma

      New York, New York
      This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2 - 25

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, Diffuse Intrinsic Pontine Tumors, Serious Medical Conditions, Others
      Must Not Be Taking:CYP3A4 Agents

      300 Participants Needed

      Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma

      New York, New York
      This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:IDH Mutation, Bevacizumab, Transplant, Others
      Must Not Be Taking:Anti-PD-1, Anti-PD-L1, Anti-CTLA-4, Others

      59 Participants Needed

      Debio 0123 + Temozolomide for Glioblastoma

      New York, New York
      This trial is testing a new drug called Debio 0123 combined with standard treatments for adults with aggressive brain cancer. It aims to find the best dose, ensure safety, and check if it works better than current treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, LVEF Below 55%, Others
      Must Be Taking:Anti-epileptic Drugs

      116 Participants Needed

      Abemaciclib for Brain Cancer

      New York, New York
      This trial is testing a drug called abemaciclib in patients whose brain tumors have come back after treatment. The drug aims to stop the growth of cancer cells by blocking certain proteins that help them multiply. Researchers want to see both the positive and negative effects of this treatment. Abemaciclib is used primarily for treating metastatic breast cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Intracranial Hemorrhage, Active Infection, Others
      Must Not Be Taking:Antiretrovirals, EIAEDs

      64 Participants Needed

      Temozolomide + Radiation Therapy for Brain Cancer

      New York, New York
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Prior Chemotherapy, Others
      Must Not Be Taking:Chemotherapy, Anticancer Agents

      751 Participants Needed

      IDH305 for Advanced Cancer

      New York, New York
      A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac, Respiratory, Gastrointestinal, Others

      166 Participants Needed

      APX005M for Pediatric Brain Cancer

      New York, New York
      This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B cells, monocytes, and dendritic cells and stimulate cytokine release from lymphocytes and monocytes. APX005M can mediate a direct cytotoxic effect on CD40+ tumor cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:Systemic Illness, Bulky Tumor, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives

      32 Participants Needed

      Nivolumab + Ipilimumab with Surgery for Glioblastoma

      New York, New York
      This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr-89 Crefmirlimab berdoxam (optional sub-study)
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Active TB, Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Bevacizumab

      63 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Astrocytoma clinical trials in New York, NY pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Astrocytoma clinical trials in New York, NY work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Astrocytoma trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Astrocytoma is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Astrocytoma medical study in New York, NY?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Astrocytoma clinical trials in New York, NY?

      Most recently, we added 177Lu-PSMA-617 for Brain Cancer, G207 + Radiation for Pediatric Brain Tumor and Adaptive Radiotherapy for Brain Tumor to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in New York

      Anxiety Clinical Trials in New York

      Schizophrenia Clinical Trials in New York

      ADHD Clinical Trials in New York

      Bipolar Disorder Clinical Trials in New York

      Multiple Sclerosis Clinical Trials in New York

      Autism Clinical Trials in New York

      Treatment Resistant Depression Clinical Trials in New York

      Borderline Personality Disorder Clinical Trials in New York

      Social Anxiety Disorder Clinical Trials in New York

      Parkinson's Disease Clinical Trials in New York

      Alzheimer's Disease Clinical Trials in New York

      By Location

      Clinical Trials near New York, NY

      Clinical Trials near Rochester, NY

      Clinical Trials near Bronx, NY

      Clinical Trials near The Bronx, NY

      Clinical Trials near Buffalo, NY

      Clinical Trials near Brooklyn, NY

      Clinical Trials near Syracuse, NY

      Clinical Trials near Albany, NY

      Clinical Trials near Stony Brook, NY

      Clinical Trials near Manhasset, NY

      Clinical Trials near New Hyde Park, NY

      Clinical Trials near Mineola, NY

      Other People Viewed

      By Subject

      Top Clinical Trials near Hopewell, VA

      Top Clinical Trials near South Carolina

      Top Clinical Trials near Astoria, NY

      Top Clinical Trials near Goodlettsville, TN

      Top Clinical Trials near Big Rapids, MI

      24 Weight Loss Trials near Chicago, IL

      71 Clinical Trials near Missouri

      Top Clinical Trials near Charleston, WV

      Top Clinical Trials near Carson City, NV

      Top Clinical Trials near Cadillac, MI

      Top Clinical Trials near Alexandria, VA

      Top Clinical Trials near Mississippi

      By Trial

      Enzalutamide + Abiraterone + Prednisone for Prostate Cancer

      Magnetic Lymph Node Mapping for Stomach Cancer

      Pembrolizumab + Radiation Therapy for Melanoma

      Prograf vs Envarsus for Liver Transplant Patients

      Teacher-Led Mental Health Care for Children

      Fast-Track Surgery for Hip and Knee Replacement

      Gaze-Controlled Computer Game for Neurodevelopmental Disorders

      MAR002 for Safety Evaluation

      Radiation + Immunotherapy for Non-Small Cell Lung Cancer

      Sibling-Mediated Intervention for Autism

      Accelerated Radiation for Breast Cancer

      BGB-11417 + Dexamethasone + Carfilzomib for Multiple Myeloma